Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation
Bridging anticoagulation is commonly prescribed to patients with atrial fibrillation during initiation and interruption of warfarin. Guidelines recommend bridging patients at high risk of stroke, while a recent randomized trial demonstrated overall harm in a population at comparatively low risk of ischemic stroke. Theory suggests that patients at high risk of stroke and low risk of hemorrhage may benefit from bridging, but data informing patient selection are scant.
To estimate the utility and cost-effectiveness of bridging anticoagulation among patients with nonvalvular atrial fibrillation, stratified by thromboembolic and hemorrhagic risk
Cost-effectiveness analysis with lifelong time horizon, from the perspective of a third-party payer
Quality-adjusted life years (QALYs) per bridged patient; US dollars per QALY gained
Unselected patients with nonvalvular atrial fibrillation may be harmed by bridging anticoagulation. Hospital admission for bridging is almost never cost-effective, and generally harmful. Among patients carefully selected by both thromboembolic and hemorrhagic risks, outpatient bridging can be beneficial and cost-effective. Results were sensitive to how effectively heparin products reduce stroke risk.
Outpatient bridging anticoagulation can be beneficial and cost-effective for a subset of patients with nonvalvular atrial fibrillation during interruption or initiation of warfarin. Admission for bridging should be avoided.
KEY WORDSMonte Carlo method models, statistical atrial fibrillation thromboembolism anticoagulants
Compliance with Ethical Standards
Conflict of Interest
Dr. Barnes has received grant funding from NIH/NHLBI (K01HL135392) and Blue Cross-Blue Shield of Michigan, and BMS/Pfizer, as well as consulting fees from BMS/Pfizer, Portola, and Janssen. All remaining authors declare that they do not have conflict of interest.
- 2.Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5):488–494. https://doi.org/10.1161/CIRCULATIONAHA.114.011777.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69(7):871–898. https://doi.org/10.1016/j.jacc.2016.11.024.CrossRefPubMedGoogle Scholar
- 8.National Health and Nutrition Examination Survey Data (NHANES) 2011–2012. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS). Available at: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2011. Accessed: 26 Nov 2018.
- 10.United States Census Bureau. 2014 national population projections tables. Available at: https://www.census.gov/data/tables/2014/demo/popproj/2014-summary-tables.html. Accessed: 26 Nov 2018.
- 13.Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–1510. https://doi.org/10.1093/eurheartj/ehr488.CrossRefPubMedGoogle Scholar
- 17.Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014;45(5):1304–1312. https://doi.org/10.1161/STROKEAHA.113.004506.CrossRefPubMedGoogle Scholar
- 22.Guerrouij M, Uppal CS, Alklabi A, Douketis JD. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011;31(4):419–423. https://doi.org/10.1007/s11239-010-0536-7.CrossRefPubMedGoogle Scholar
- 23.Ashburner JM, Go AS, Reynolds K, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015;115(1):40–46. https://doi.org/10.1016/j.amjcard.2014.10.006.CrossRefPubMedGoogle Scholar
- 27.HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. Available at: www.hcup-us.ahrq.gov/sidoverview.jsp. Accessed: 26 Nov 2018.
- 29.Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO Global Burden of Disease Project disability weights for each level of the modified Rankin scale * Supplemental Mathematical Appendix. Stroke. 2009;40(12):3828–3833. https://doi.org/10.1161/STROKEAHA.109.561365. CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Bureau of Labor Statistics, May 2011. Occupational employment statistics, U.S. Department of Labor. Available at: https://www.bls.gov/oes/tables.htm. Accessed 26 Nov 2018.
- 32.Luengo-Fernandez R, Paul NLM, Gray AM, et al. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke. 2013;44(10):2854–2861. https://doi.org/10.1161/STROKEAHA.113.001584.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Azoulay L, Dell'Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord. 2012;12(1):49. https://doi.org/10.1186/1471-2261-12-49. CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–1639. https://doi.org/10.1161/CIRCULATIONAHA.112.105221.CrossRefPubMedGoogle Scholar
- 40.Historical exchange rates tool & Forex history data | OFX. Available at: https://www.ofx.com/en-us/forex-news/historical-exchange-rates/. Accessed 26 Nov 2018.